1st Quarter - Report

GENZYME CORPORATION for GENZYME CORPORATION

Firm
Client
Income
—
Expenses
$640,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

S. 1145, Patent Reform Act of 2007 HR. 1908, Patent Reform Act of 2007 H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H.R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, Follow-on Biologics S. 623, Access to Life-Saving Medicine Act, follow-on biologics

LobbyistCovered position, as disclosed
SARA FROELICH Vice President
KATHLEEN HOLCOMBE Senior Policy Advisor
MARY MCGRANE Senior Vice President

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Bills named: H.R. 1908 (110th), H.R. 5629 (110th), S. 1145 (110th), S. 1505 (110th), H.R. 1956 (110th), S. 1695 (110th), S. 623 (110th), H.R. 1038 (110th)

Medicare/Medicaid MMM

H.R. 2606, 340B Program Improvement and Integrity Act of 2007, 340 B drug price expansion H.R. 3162, Children's Health and Medicare Protection Act of 2007 H.R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provisions H.R. 5480, Medicare Funding Warning Response Act of 2008 S. 1376, 340B Program Improvement and Integrity Act of 2007, 340 B Drug price expansion S. 2029, Physician Payments Sunshine Act of 2007 S. 2662, Medicare Funding Warning Response Act of 2008 S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provision Comparative Effectiveness S. 2099 "Preserving Access to Laboratory Services Act of 2007" Repeal of competitive bidding demo Bundling payment system for dialysis centers Medicare prescription drug benefit H.R. 1321 "Medicare Advanced Laboratory Diagnostics Act of 2007" S.2404 "The Medicare Advanced Laboratory Diagnostic Act of 2007" S.691/H.R. 1193 The Kidney Care Quality and Education Act CPT Coding decisions and HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital outpatient departments, dialysis centers and physician officers. Physicians fee schedule payment rates for lab tests. Medicaid rebates H.R. 2184, the Enhanced Health Care Value for All Act

LobbyistCovered position, as disclosed
SARA FROELICH Vice President
KATHLEEN HOLCOMBE Senior Policy Advisor
MARY MCGRANE Senior Vice President

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Bills named: S. 1376 (110th), H.R. 2606 (110th), H.R. 5480 (110th), H.R. 3162 (110th), H.R. 1193 (110th), S. 2029 (110th), S. 2662 (110th), S. 2404 (110th), S. 691 (110th), H.R. 2184 (110th), S. 3 (110th), S. 2099 (110th), H.R. 4 (110th), H.R. 1321 (110th)

Pharmacy PHA

H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H.R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, Follow-on Biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 623, Access to Life-Saving Medicine Act, follow-on biologics Neglected Disease Issues Issues related to Drug Safety, Generic Biologics & Drug Approvals H.R. 380, "Pharmaceutical Market Access and Drug Safety act of 2007" - Importation. S.251, Pharmaceutical Market Access & Drug Safety Act of 2007" - Importation. S.242, "Pharmaceutical Market Access & Drug Safety Act of 2007" H.R. 1561, Enhancing Drug Safety and Innovation Act of 2007

LobbyistCovered position, as disclosed
SARA FROELICH Vice President
KATHLEEN HOLCOMBE Senior Policy Advisor
MARY MCGRANE Senior Vice President

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Bills named: H.R. 5629 (110th), S. 251 (110th), S. 242 (110th), S. 623 (110th), H.R. 1561 (110th), H.R. 380 (110th), S. 1695 (110th), S. 2029 (110th), S. 1505 (110th), H.R. 1956 (110th), H.R. 1038 (110th)

Medical/Disease Research/Clinical Labs MED

H.R. 3453, Community Clinical Laboratory Fairness in Competition Act of 2007 Reimbursement for clinical lab services under Medicare H.R. 1321 "Medicare Advanced Laboratory Diagnostics Act"; S.2404 "The Medicare Advanced Laboratory Diagnostic Act of 2007" S.976 "Genomics & Personalized Medicine Act of 2007" Competitive bidding for lab tests S.736, "The Laboratory Test Improvement Act"

LobbyistCovered position, as disclosed
SARA FROELICH Vice President
KATHLEEN HOLCOMBE Senior Policy Advisor
MARY MCGRANE Senior Vice President

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1321 (110th), S. 2404 (110th), H.R. 3453 (110th), S. 736 (110th), S. 976 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.